BSE Live
Apr 10, 16:01Prev. Close
39.58
Open Price
40.15
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 10, 16:00Prev. Close
39.61
Open Price
40.00
Bid Price (Qty.)
40.16 (2099)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Morepen Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 137.59 | 148.98 | 63.04 | 125.54 | 94.25 | |
| Net CashFlow From Operating Activities | 29.08 | 77.36 | -102.12 | -66.38 | 49.31 | |
| Net Cash Used In Investing Activities | -280.42 | -83.60 | -36.20 | -22.64 | -69.09 | |
| Net Cash Used From Financing Activities | 260.47 | 0.28 | 144.20 | 63.93 | 47.46 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 9.12 | -5.96 | 5.88 | -25.09 | 27.68 | |
| Cash And Cash Equivalents Begin of Year | 15.30 | 21.26 | 15.38 | 40.47 | 12.79 | |
| Cash And Cash Equivalents End Of Year | 24.43 | 15.30 | 21.26 | 15.38 | 40.47 |
16.03.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
20.02.2026
Morepen Lab Consolidated December 2025 Net Sales at Rs 484.16 crore, up 6.93% Y-o-Y
19.02.2026
Morepen Lab Standalone December 2025 Net Sales at Rs 457.57 crore, up 13.47% Y-o-Y
26.11.2025
Morepen Lab Consolidated September 2025 Net Sales at Rs 411.58 crore, down 5.97% Y-o-Y
10.04.2026
09.04.2026
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth